BioBDx develops and markets a proprietary platform technology to objectively measure specific behaviors that correlate with brain function and deficits in inhibitory control. The company’s first product is Quotient, an FDA-cleared tool as an aid in the assessment of ADHD. The product is currently used by neurologists, pediatricians, psychiatrists and psychologists across the U.S. and supported be key opinion leaders worldwide. The company’s technology has broad applicability to other central nervous systems diseases.
BioBDx was seeking a partner that would enable the company to expand and serve new markets.
Pearson acquired BioBDx. This acquisition marks a strategic entry into healthcare markets for Pearson, and opens a new market for BioBDx. With Pearson’s support, the Quotient ADHD Test will reach beyond the pediatric, neurology and psychiatry offices throughout the U.S. and expand to mental health and educational professionals. Sikich was a true partner to BioBDx throughout the acquisition, from engagement to closure. The process was remarkably efficient and the Sikich team ensured that all the critical path diligence issues were effectively addressed in a timely manner. With the support of Pearson, the BioBDx team is excited about the potential for the real impact BioBDx can make for individuals living with ADHD.